R Hirsch, R E Gress, J A Bluestone. Show Affiliations »
Abstract
Entities: Disease
Mesh: See more » Antibodies, Monoclonal/adverse effectsAutoimmune Diseases/drug therapyHumansImmunosuppressionLymphocyte Activation/drug effectsMuromonab-CD3Product Surveillance, Postmarketing
Substances: See more » Antibodies, MonoclonalMuromonab-CD3
Year: 1989 PMID: 2567402 DOI: 10.1016/s0140-6736(89)92835-3
Source DB: PubMed Journal: Lancet ISSN: 0140-6736 Impact factor: 79.321